

510(k) Summary

K080106
P1/1

SUBMITTER

Submitted on behalf of:

Company Name:

Leonhard Lang GmbH

Address:

Archenweg 56
6020 Innsbruck
Austria

Telephone:

++ 43 / 512 / 33 4 25 7

Fax:

++ 43 / 512 / 39 22 10

Registration Number:

8020045

Owner/operator Number: 8020045

by:

Elaine Duncan, MS.M.E., RAC
President, Paladin Medical, Inc.
PO Box 560
Stillwater, MN 55082
Telephone: 715-549-6035
Fax: 715-549-5380

FEB - 1 2008

Contact Person:

Elaine Duncan

Date prepared:

January 11, 2007

Trade Name:

Skintact® Pre-wired ECG Electrodes with Conductive Adhesive
(and as also to be offered for sale under various private label tradenames)

Common Name:

Disposable ECG Electrodes

Classification Name:

Electrocardiograph (ECG) Electrode

Regulation:

Electrocardiographic electrode, 21 CFR 870.2360

Regulatory Class

This device is Class II

Device Panel and Product Code: Cardiovascular: 74 DRX

Reason for 510(k) Submission: addition of pre-attached lead wire

Substantial Equivalence: Skintact® Pre-wired ECG Electrodes with Conductive Adhesive are substantially equivalent to K073104 Leonhard Lang Skintact® ECG Electrodes with Conductive Adhesive and have the same indications for use. The only change between the original Skintact® ECG Electrodes with Conductive Adhesive and the Skintact® Pre-wired ECG Electrodes with Conductive Adhesive is the addition of pre-attached lead wire. No new technology is required for this change since ECG Electrodes with pre-attached lead wires have been previously cleared in predicate devices using similar materials:

K000206 Pals Neonatal Pediatric ECG Electrode

K053011 Pro-Neo Neonatal ECG Electrode

K053550 Ambu Blue sensor Neo and Neo X

Description of device: All Skintact® ECG Electrodes are self-adhesive, non-sterile, single use disposable electrodes. The Skintact® Pre-wired ECG Electrodes with Conductive Adhesive are composed of the same materials as the predicate devices by Leonhard Lang except the pre-attached lead wire. The lead wires are similar to those in predicate devices.

Indications for use: Skintact® ECG Electrodes are designed for use in general electrocardiographic procedures where ECG monitoring is deemed necessary and is ordered by a physician. Such procedures include in particular patient ECG surveillance and ECG diagnosis recording. Skintact® ECG Electrodes are single-use, non-sterile and disposable and are to be used on intact (uninjured) skin.

Basis for Equivalence - performance testing: Biocompatibility testing was cleared in predicate devices and passed ISO 10993 for intact skin. According to the performance data, Leonhard Lang Skintact® Pre-wired ECG Electrodes with Conductive Adhesive met specifications as established in ANSI/AAMI EC12:2000, as did the predicate devices (K073104, K000206, K053011, K053550). The shelf life of Skintact® Pre-wired ECG Electrodes with Conductive Adhesive was tested in accelerated aging in the same manner as the predicate device K073104. The introduction of the Skintact® Pre-wired ECG Electrodes with Conductive Adhesive (and as also to be offered for sale under various private label tradenames) does not introduce new issues of safety or effectiveness.



FEB - 1 2008

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Leonhard Lang GMBH
c/o Ms. Elaine Duncan, MS.M.E, RAC
President, Paladin Medical, Inc.
P.O. Box 560
Stillwater, MN 55082-0560

Re: K080106
Skintact® Pre-wired ECG Electrodes with Conductive Adhesive
Regulation Number: 21 CFR 870.2360
Regulation Name: Electrocardiograph electrode
Regulatory Class: Class II (two)
Product Code: DRX
Dated: January 11, 2008
Received: January 15, 2008

Dear Ms. Duncan:


We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman" followed by a stylized flourish.

Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

